• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用基于成像的ATN生物标志物的多模态规范模型分析阿尔茨海默病的异质性。

Analyzing heterogeneity in Alzheimer Disease using multimodal normative modeling on imaging-based ATN biomarkers.

作者信息

Kumar Sayantan, Earnest Tom, Yang Braden, Kothapalli Deydeep, Aschenbrenner Andrew J, Hassenstab Jason, Xiong Chengie, Ances Beau, Morris John, Benzinger Tammie L S, Gordon Brian A, Payne Philip, Sotiras Aristeidis

机构信息

Department of Computer Science and Engineering, Washington University in St Louis; 1 Brookings Drive, Saint Louis, MO 63130.

Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine in St Louis; 660 S. Euclid Ave, Campus Box 8132, Saint Louis, MO 63110.

出版信息

ArXiv. 2024 Jul 1:arXiv:2404.05748v2.

PMID:39010871
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11247918/
Abstract

INTRODUCTION

Previous studies have applied normative modeling on a single neuroimaging modality to investigate Alzheimer Disease (AD) heterogeneity. We employed a deep learning-based multimodal normative framework to analyze individual-level variation across ATN (amyloid-tau-neurodegeneration) imaging biomarkers.

METHODS

We selected cross-sectional discovery (n = 665) and replication cohorts (n = 430) with available T1-weighted MRI, amyloid and tau PET. Normative modeling estimated individual-level abnormal deviations in amyloid-positive individuals compared to amyloid-negative controls. Regional abnormality patterns were mapped at different clinical group levels to assess intra-group heterogeneity. An individual-level disease severity index (DSI) was calculated using both the spatial extent and magnitude of abnormal deviations across ATN.

RESULTS

Greater intra-group heterogeneity in ATN abnormality patterns was observed in more severe clinical stages of AD. Higher DSI was associated with worse cognitive function and increased risk of disease progression.

DISCUSSION

Subject-specific abnormality maps across ATN reveal the heterogeneous impact of AD on the brain.

摘要

引言

以往的研究已将规范建模应用于单一神经影像学模态,以研究阿尔茨海默病(AD)的异质性。我们采用了基于深度学习的多模态规范框架,来分析跨ATN(淀粉样蛋白- tau-神经退行性变)成像生物标志物的个体水平差异。

方法

我们选择了有可用T1加权MRI、淀粉样蛋白和tau PET数据的横断面发现队列(n = 665)和复制队列(n = 430)。规范建模估计了淀粉样蛋白阳性个体与淀粉样蛋白阴性对照相比的个体水平异常偏差。在不同临床组水平绘制区域异常模式,以评估组内异质性。使用跨ATN异常偏差的空间范围和大小计算个体水平的疾病严重程度指数(DSI)。

结果

在AD更严重的临床阶段,观察到ATN异常模式中更大的组内异质性。较高的DSI与较差的认知功能和疾病进展风险增加相关。

讨论

跨ATN的个体特异性异常图谱揭示了AD对大脑的异质性影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/521b/11247918/739e03fdf854/nihpp-2404.05748v2-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/521b/11247918/73798e08e8b3/nihpp-2404.05748v2-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/521b/11247918/26dabfd893b2/nihpp-2404.05748v2-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/521b/11247918/6a082c099954/nihpp-2404.05748v2-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/521b/11247918/b1f832fbbf3c/nihpp-2404.05748v2-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/521b/11247918/bd0de4373a08/nihpp-2404.05748v2-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/521b/11247918/739e03fdf854/nihpp-2404.05748v2-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/521b/11247918/73798e08e8b3/nihpp-2404.05748v2-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/521b/11247918/26dabfd893b2/nihpp-2404.05748v2-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/521b/11247918/6a082c099954/nihpp-2404.05748v2-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/521b/11247918/b1f832fbbf3c/nihpp-2404.05748v2-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/521b/11247918/bd0de4373a08/nihpp-2404.05748v2-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/521b/11247918/739e03fdf854/nihpp-2404.05748v2-f0006.jpg

相似文献

1
Analyzing heterogeneity in Alzheimer Disease using multimodal normative modeling on imaging-based ATN biomarkers.使用基于成像的ATN生物标志物的多模态规范模型分析阿尔茨海默病的异质性。
ArXiv. 2024 Jul 1:arXiv:2404.05748v2.
2
Analyzing heterogeneity in Alzheimer disease using multimodal normative modeling on imaging-based ATN biomarkers.使用基于成像的ATN生物标志物的多模态规范模型分析阿尔茨海默病的异质性。
Alzheimers Dement. 2025 Apr;21(4):e70143. doi: 10.1002/alz.70143.
3
Analyzing heterogeneity in Alzheimer Disease using multimodal normative modeling on imaging-based ATN biomarkers.使用基于成像的ATN生物标志物的多模态规范模型分析阿尔茨海默病的异质性。
bioRxiv. 2024 Jun 30:2023.08.15.553412. doi: 10.1101/2023.08.15.553412.
4
Impact of diabetes on the progression of Alzheimer's disease via trajectories of amyloid-tau-neurodegeneration (ATN) biomarkers.糖尿病通过淀粉样蛋白- tau-神经变性(ATN)生物标志物轨迹对阿尔茨海默病进展的影响。
J Nutr Health Aging. 2025 Feb;29(2):100444. doi: 10.1016/j.jnha.2024.100444. Epub 2024 Dec 10.
5
Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.50-95岁认知未受损个体中脑β淀粉样变性、tau蛋白病和神经退行性变的年龄及性别特异性患病率:一项横断面研究
Lancet Neurol. 2017 Jun;16(6):435-444. doi: 10.1016/S1474-4422(17)30077-7. Epub 2017 Apr 26.
6
MRI-based Deep Learning Assessment of Amyloid, Tau, and Neurodegeneration Biomarker Status across the Alzheimer Disease Spectrum.基于 MRI 的深度学习对阿尔茨海默病谱中淀粉样蛋白、tau 及神经退行性变生物标志物状态的评估。
Radiology. 2023 Oct;309(1):e222441. doi: 10.1148/radiol.222441.
7
Exploring the ATN classification system using brain morphology.探索使用大脑形态学的 ATN 分类系统。
Alzheimers Res Ther. 2023 Mar 13;15(1):50. doi: 10.1186/s13195-023-01185-x.
8
Highly specific amyloid and tau PET ligands for ATN classification in suspected Alzheimer's disease patients.用于疑似阿尔茨海默病患者ATN分类的高度特异性淀粉样蛋白和tau PET配体。
Ann Nucl Med. 2025 May;39(5):458-465. doi: 10.1007/s12149-025-02018-7. Epub 2025 Jan 28.
9
Alzheimer's disease diagnostic accuracy by fluid and neuroimaging ATN framework.基于液质和神经影像学阿尔茨海默病诊断准确性框架
CNS Neurosci Ther. 2024 Feb;30(2):e14357. doi: 10.1111/cns.14357. Epub 2023 Jul 12.
10
Associations between different tau-PET patterns and longitudinal atrophy in the Alzheimer's disease continuum: biological and methodological perspectives from disease heterogeneity.不同 tau-PET 模式与阿尔茨海默病连续体中纵向萎缩的相关性:疾病异质性的生物学和方法学观点。
Alzheimers Res Ther. 2023 Feb 22;15(1):37. doi: 10.1186/s13195-023-01173-1.

本文引用的文献

1
Data-driven decomposition and staging of flortaucipir uptake in Alzheimer's disease.基于数据驱动的阿尔茨海默病氟脱氧葡萄糖摄取的分解和分期。
Alzheimers Dement. 2024 Jun;20(6):4002-4019. doi: 10.1002/alz.13769. Epub 2024 Apr 29.
2
Alzheimer's disease heterogeneity revealed by neuroanatomical normative modeling.通过神经解剖学规范建模揭示的阿尔茨海默病异质性
Alzheimers Dement (Amst). 2024 Mar 13;16(1):e12559. doi: 10.1002/dad2.12559. eCollection 2024 Jan-Mar.
3
Normative Modeling using Multimodal Variational Autoencoders to Identify Abnormal Brain Volume Deviations in Alzheimer's Disease.
使用多模态变分自编码器的规范建模以识别阿尔茨海默病中的异常脑容量偏差
Proc SPIE Int Soc Opt Eng. 2023 Feb;12465. doi: 10.1117/12.2654369. Epub 2023 Apr 7.
4
A data-driven study of Alzheimer's disease related amyloid and tau pathology progression.基于数据的阿尔茨海默病相关淀粉样蛋白和tau 病理进展研究。
Brain. 2023 Dec 1;146(12):4935-4948. doi: 10.1093/brain/awad232.
5
Prognostic value of imaging-based ATN profiles in a memory clinic cohort.基于影像学的 ATN 谱在记忆门诊队列中的预后价值。
Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3313-3323. doi: 10.1007/s00259-023-06311-3. Epub 2023 Jun 26.
6
Lecanemab: Appropriate Use Recommendations.仑卡奈单抗:合理使用建议。
J Prev Alzheimers Dis. 2023;10(3):362-377. doi: 10.14283/jpad.2023.30.
7
Revealing Individual Neuroanatomical Heterogeneity in Alzheimer Disease Using Neuroanatomical Normative Modeling.利用神经解剖学规范建模揭示阿尔茨海默病中的个体神经解剖学异质性。
Neurology. 2023 Jun 13;100(24):e2442-e2453. doi: 10.1212/WNL.0000000000207298. Epub 2023 May 1.
8
Distinct spatiotemporal subtypes of amyloid deposition are associated with diverging disease profiles in cognitively normal and mild cognitive impairment individuals.在认知正常和轻度认知障碍个体中,淀粉样蛋白沉积具有不同的时空亚型,与不同的疾病特征相关。
Transl Psychiatry. 2023 Feb 2;13(1):35. doi: 10.1038/s41398-023-02328-2.
9
The ATN Framework-Moving Preclinical Alzheimer Disease to Clinical Relevance.ATN框架——将临床前阿尔茨海默病转化为具有临床相关性的研究
JAMA Neurol. 2022 Oct 1;79(10):968-970. doi: 10.1001/jamaneurol.2022.2967.
10
Disentangling tau and brain atrophy cluster heterogeneity across the Alzheimer's disease continuum.解析阿尔茨海默病连续体中tau蛋白和脑萎缩簇的异质性。
Alzheimers Dement (N Y). 2022 May 23;8(1):e12305. doi: 10.1002/trc2.12305. eCollection 2022.